[Topical immune modulation and risk of cancer].
This article reviews if local immunosuppression of atopic dermatitis is associated with an increased risk of cancer - as implicated by a warning issued by the FDA and EMEA health authorities because systemic immunosuppression of transplanted patients leads to a significant increase of non-melanoma skin cancer and lymphoma. So far, no studies support that the use of topical immunosuppression increases the risk of local or systemic cancer.
Deleuran
Mette
M
Dermatologisk Afdeling S, Arhus Universitetshospital, Arhus Sygehus, DK-8000 Arhus C. m.deleuran@dadlnet.dk
Zachariae
Claus
C
Thestrup-Pedersen
Kristian
K
D000287:Administration, Topical; D000328:Adult; D002648:Child; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008223:Lymphoma / Q000139:chemically induced; D012307:Risk Factors; D012878:Skin Neoplasms / Q000139:chemically induced; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus